Search results
Results From The WOW.Com Content Network
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer: GDP gemcitabine, dexamethasone, cisplatin: Non-Hodgkin lymphomas and Hodgkin lymphoma: GemOx or GEMOX: gemcitabine, oxaliplatin: Non-Hodgkin lymphomas: GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin: Hodgkin lymphoma: GemOx-R or GEMOX-R or R-GemOx ...
Gemcitabine is a synthetic pyrimidine nucleoside prodrug—a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. [ 3 ] [ 24 ] [ 25 ] The synthesis described and pictured below is the original synthesis done in the Eli Lilly Company labs.
Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. [37] [38] They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. [41] Non-classical alkylating agents include procarbazine and hexamethylmelamine. [37] [38]
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...
It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R. [R]-DHAP regimen consists of: Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
NHS efficiency savings of 2% to 3% a year from 2015 to 2021 were supposed to save £22 billion a year. Between 2004 and 2014 NHS output increased considerably. Hospital admissions increased by 32%, outpatient attendances by 17%, primary care consultations by 25% and community care activity by 14%.